Sr. Financial Analyst, R&D Finance (Hybrid)

At 4D Molecular Therapeutics, Inc. (“4DMT”), we boldly innovate to unlock the full potential of genetic medicines for countless patients. We are committed to breaking boundaries and daring to cure as we develop new and foundational products and product components through our growing technology platforms.4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution (TVE), which combines the power of directed evolution with our approximately one billion synthetic AAV capsid-derived sequences to invent evolved vectors for use in our products. We believe key features of our targeted and evolved vectors will help us create targeted product candidates with improved therapeutic profiles. These profiles will allow us to treat a broad range of large market diseases, unlike most current genetic medicines that generally focus on rare or small market diseases.We have built a deep portfolio of AVV-based gene therapy product candidates, with five product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, we have two product candidates in preclinical studies: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency.To-date, we have demonstrated clinical proof-of-concept for three evolved vectors in three therapeutic areas and routes of administration with five products and patient populations. We believe this validates the power of our directed evolution platform for discovering superior vectors compared to wildtype viral vectors. We have built a robust and efficient product engine with 6 open Investigational New Drug Applications (INDs) in the U.S., 1 IND in Taiwan, and 1 Clinical Trial Approval (CTA) in Australia. We believe we are positioned to create, develop, manufacture and, if approved, effectively commercialize targeted genetic medicines that could transform the lives of patients suffering from debilitating diseases.In addition to TVE, our technology includes a robust AAV manufacturing platform and onsite manufacturing facility that allows us to rapidly produce and test research grade material and scale up to GMP clinical material. This internal capability and close collaboration between our R&D and Manufacturing teams has greatly accelerated the pace of discovery at 4DMT.GENERAL SUMMARY:The Senior Financial Analyst, R&D Finance will be a key member in a growing and dynamic organization. Reporting to the Director, FP&A, the ideal candidate will be hands-on and responsible for managing clinical trial, program and functional budgets, preparing detailed accruals, reviewing and analyzing contracts, financial modeling and partnering with R&D leaders. The candidate should have exceptional business collaboration skills with an eye towards process improvements and providing insightful analysis to drive decision-making.*This role is hybrid, with remote work and ~2+ days a week in our Emeryville office.*JOB DUTIES:Serve as a key finance business partner to the entire R&D organization, including Development, Technical Operations/CMC, Clinical, Regulatory and Quality teams.Create and/or update financial models for R&D pipeline programs to support decision-making and provide key insights.Manage the month-end close for R&D to ensure the accuracy and completeness of Clinical Trial accruals, prepayments and recording journal entries.Review and track R&D vendor agreements.Develop financial reports, including monthly and quarterly financial packages with variance reporting to budget and prior periods.Assist with trend and variance analysis for Clinical and CMC costs and accrual balances.Partner with the Accounting team to establish and maintain SOX-compliant financial processes.Assist with external audit requests and PBC items for quarterly and year-end audits.Assess current processes and continuously push for improvement.Participate in other ad-hoc projects and analyses as needed.Other duties as assigned, nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time.QUALIFICATIONS:Education:Bachelor’s or equivalent degree in accounting, finance or business administration.CPA a plus.Experience:A minimum of 5 years of biotech/pharma experience supporting R&D development.Proficient in Excel and the Microsoft Office suite.Experience with NetSuite is desirable.Experience with a cloud-based financial planning system (Adaptive, Anaplan, Planful etc…) is desirable.Experience working for a public company.Skills:A focus on meeting assigned deadlines.Attention to detail and ability to multitask.Excellent understanding of US GAAP.Excellent communication and administrative skills.Exceptional organization and time management skills.Base salary compensation range:Bay Area Range: $111,000/yr - $136,000/yr.Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities

#J-18808-Ljbffr